Associated tags: Patient, University, Osaka University, Kyoto University, Regulatory T cell, Vaccine, Immunoglobulin G, ISID, Keio University, Kyoto, Pemphigus
Locations: JAPAN, BERKELEY, VIRGINIA
Cell,
Rachel Haurwitz,
Drug discovery,
Genetics,
Inflammation,
Patient,
Arrowhead Pharmaceuticals,
Research,
Bristol Myers Squibb,
University,
Publication,
Reindeer,
Microbiology,
Regulatory T cell,
RNA interference,
Immune system,
Therapy,
Bangladesh Technical Education Board,
Book,
Astex Pharmaceuticals,
Vaccine "We are honored to have Steve Kanner join our Board of Directors," remarked Professor Shimon Sakaguchi, co-founder of RegCell.
Key Points:
- "We are honored to have Steve Kanner join our Board of Directors," remarked Professor Shimon Sakaguchi, co-founder of RegCell.
- "Dr. Kanner's profound understanding of immunology comes at a pivotal juncture for RegCell as we advance our clinical development and expand our Precision Epigenetic Reprogramming Platform.
- Backed by leading institutional and corporate investors hailing from Japan, RegCell emerges as the next-generation global life science enterprise at the forefront of regulatory T-cell therapies.
- Central to RegCell's innovation is its 'Precision Epigenetic Reprogramming' platform, which entails the epigenetic reprogramming of CD4+ T-cells into regulatory T-cells.
Retrieved on:
Thursday, October 19, 2023
Osaka University,
FDA,
Immune tolerance,
Food,
Biotechnology,
Business development,
Acquisition,
MBA,
Regulation of tobacco by the U.S. Food and Drug Administration,
Research,
Otsuka Pharmaceutical,
Supergene,
Syndrome,
Drug development,
Senior,
U.S. Department of Defense Strategy for Operating in Cyberspace,
Technical advisor,
Immune system,
Business,
Sumitomo Pharma,
Kyoto University,
Patient,
Astex Pharmaceuticals,
Toxic epidermal necrolysis,
Pharmaceutical industry,
Vaccine,
Regulatory T cell,
Decitabine "I am honored to join this remarkable team at an exciting time for RegCell as we prepare to enter the clinical stage and to support the company's mission to discover innovative treatments for autoimmune diseases," said Dr. Michael McCullar, Chief Executive Officer of RegCell.
Key Points:
- "I am honored to join this remarkable team at an exciting time for RegCell as we prepare to enter the clinical stage and to support the company's mission to discover innovative treatments for autoimmune diseases," said Dr. Michael McCullar, Chief Executive Officer of RegCell.
- "In an era where the increasingly aging population is facing an escalating burden of autoimmune disorders, Treg-based cellular therapies are opening the doors to exciting new treatment possibilities.
- Dr. McCullar has a wealth of experience in the biotech and pharmaceutical industries, spanning more than two decades.
- Dr. McCullar has held several high-level executive positions at SuperGen, showcasing his commitment and upward career path within the company.
OSAKA, Japan, May 29, 2023 /PRNewswire/ -- RegCell collaborators from Keio University and Osaka University presented key data at ISID 2023 Tokyo Satellite Meeting.
Key Points:
- OSAKA, Japan, May 29, 2023 /PRNewswire/ -- RegCell collaborators from Keio University and Osaka University presented key data at ISID 2023 Tokyo Satellite Meeting.
- Their presentation demonstrated that in a murine pemphigus model, S/F-iTregs significantly decreased clinical scores, circulating anti-Dsg3 IgG titers, and other autoimmune markers related to Pemphigus.
- Collaborators also reported that S/F-iTregs generated from samples obtained from patients with Pemphigus also showed potent inhibition of autologous T cell proliferation in vitro.
- Tregs play a central role in managing immune self-tolerance and depleted or dysfunctional Tregs are characteristic of many autoimmune disorders.
OSAKA, Japan, May 29, 2023 /PRNewswire/ -- RegCell collaborators from Keio University and Osaka University presented key data at ISID 2023 Tokyo Satellite Meeting.
Key Points:
- OSAKA, Japan, May 29, 2023 /PRNewswire/ -- RegCell collaborators from Keio University and Osaka University presented key data at ISID 2023 Tokyo Satellite Meeting.
- Their presentation demonstrated that in a murine pemphigus model, S/F-iTregs significantly decreased clinical scores, circulating anti-Dsg3 IgG titers, and other autoimmune markers related to Pemphigus.
- Collaborators also reported that S/F-iTregs generated from samples obtained from patients with Pemphigus also showed potent inhibition of autologous T cell proliferation in vitro.
- Tregs play a central role in managing immune self-tolerance and depleted or dysfunctional Tregs are characteristic of many autoimmune disorders.
